Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Imugene ( (AU:IMU) ) is now available.
Imugene Limited has announced promising results from its Phase 1b clinical trial of azer-cel, an allogeneic CD19 CAR T therapy, in patients with relapsed diffuse large B-cell lymphoma (DLBCL). The trial has achieved a 79% overall response rate, with six complete responses and five partial responses, indicating significant potential for azer-cel in treating this aggressive form of blood cancer. The trial is expanding to include CAR T naïve patients with other types of lymphomas, and the safety profile of the treatment is manageable and well-tolerated. These developments could enhance Imugene’s position in the immuno-oncology field and provide new treatment options for patients with high unmet needs.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a clinical-stage immuno-oncology company focused on developing innovative cancer therapies. The company is engaged in the development of allogeneic CAR T-cell therapies, which aim to address limitations of current autologous CAR T drugs, such as geographical access, manufacturing complexity, and treatment time.
YTD Price Performance: -80.13%
Average Trading Volume: 1,118,654
Technical Sentiment Signal: Sell
Current Market Cap: A$72.12M
See more insights into IMU stock on TipRanks’ Stock Analysis page.